Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost.

被引：1
|
作者：
Moskovitz, Mor Tal
Matthews, Priscilla M.
Pavel, Alexandra M.
Xu, Wei
Bradbury, Penelope Ann
Liu, Geoffrey
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 05期
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
174
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Early Immune-Related Adverse Events Under PD-1/PD-L1 Inhibitors Predict Better Progression-Free Survival in NSCLC
    Boussageon, M.
    Ortiz-Cuaran, S.
    Chabaud, S.
    Perol, D.
    Avrillon, V.
    Mastroianni, B.
    Fayette, J.
    Ghiringhelli, F.
    Neidhardt, E.
    Swalduz, A.
    Paulus, V.
    Kaderbhai, C.
    Fumet, J.
    Saintigny, P.
    Perol, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S407 - S407
  • [42] Assessing the impact of PD-1/PD-L1 inhibitors on health and budget in Belgium
    van Bavel, J.
    Lucherini, S.
    Vermeersch, S.
    Abreu, A. Bento
    Davies, N.
    Okhuoya, P.
    Pellisier, J.
    Roediger, A.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2018, 28 : 439 - 439
  • [43] Projecting the budget and health impact of PD-1/PD-L1 inhibitors in Slovenia
    van Bavel, J.
    Lucherini, S.
    Rajer, M.
    Jovanovic, S. Derviskadic
    Krizaj, Z.
    Burnik, T.
    Davies, N.
    Toghanian, S.
    Pellisier, J.
    Roediger, A.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2018, 28 : 438 - 438
  • [44] The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
    Cai, Jiajing
    Qi, Qi
    Qian, Xuemeng
    Han, Jia
    Zhu, Xinfang
    Zhang, Qi
    Xia, Rong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (06) : 1377 - 1385
  • [45] The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
    Jiajing Cai
    Qi Qi
    Xuemeng Qian
    Jia Han
    Xinfang Zhu
    Qi Zhang
    Rong Xia
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 1377 - 1385
  • [46] Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC
    Wang, D.
    Feng, Y.
    Wang, H.
    Peng, H.
    Zhang, W.
    Su, W.
    Li, H.
    Hu, B.
    Bai, Y.
    Ma, H.
    Huang, L.
    Zhu, T.
    Qian, H.
    Li, Y.
    Fang, X.
    Ren, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S618 - S618
  • [47] ctDNA a promising predictive marker for treatment with PD-1 inhibitors in KRAS mutated NSCLC after platinum based chemotherapy
    Hiltermann, T. Jeroen. N.
    Hijmering-Kappelle, Lucie B. M.
    Azpurua, Maria L. Aguirre
    vd Wekken, Anthonie. J.
    Hiddinga, Birgitta. L.
    Timens, Wim
    Groen, Harry. J. M.
    Schuuring, Ed
    CANCER RESEARCH, 2019, 79 (13)
  • [48] The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors
    Nuvola, Giacomo
    Mollica, Veronica
    Massari, Francesco
    Suarez, Cristina
    IMMUNOTHERAPY, 2023, 15 (17)
  • [49] PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
    Zhu, Yixiang
    Zhang, Ye
    Hu, Xingsheng
    Wang, Mingzhao
    Wang, Hongyu
    Liu, Yutao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (12) : 3557 - 3566
  • [50] The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment
    Xu, Mengdan
    Li, Shenglong
    CANCER LETTERS, 2024, 593
12345